Hisamitsu Pharmaceutical Co (FRA:HPX) Total Liabilities: €394.2 Mil (As of Nov. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:HPX Hisamitsu Pharmaceutical Co Inc FRA:HPX
65 GF Score
Price €31.80
GF Value €25.90
View Full Analysis

What is Hisamitsu Pharmaceutical Co Total Liabilities?

Hisamitsu Pharmaceutical Co FRA:HPX 65 Total Liabilities is €394.2 Mil as of Nov. 2025. GuruFocus rates FRA:HPX with a GF Score™ of 65/100 and a GF Value™ of €25.90.

Hisamitsu Pharmaceutical Co's Total Liabilities for the quarter that ended in Nov. 2025 was €394.2 Mil.

Hisamitsu Pharmaceutical Co's quarterly Total Liabilities increased from May. 2025 (€379.62 Mil) to Aug. 2025 (€393.03 Mil) and increased from Aug. 2025 (€393.03 Mil) to Nov. 2025 (€394.18 Mil).

Hisamitsu Pharmaceutical Co's annual Total Liabilities increased from Feb. 2024 (€382.31 Mil) to Feb. 2025 (€403.23 Mil) but then declined from Feb. 2025 (€403.23 Mil) to Feb. 2026 (€395.30 Mil).

Hisamitsu Pharmaceutical Co Total Liabilities Historical Data

* Premium members only.

The historical data trend for Hisamitsu Pharmaceutical Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hisamitsu Pharmaceutical Co Total Liabilities Chart

Hisamitsu Pharmaceutical Co Annual Data
Trend Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24 Feb25 Feb26
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 366.66 389.71 382.31 403.23 395.30

Hisamitsu Pharmaceutical Co Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 403.23 379.62 393.03 394.18 395.30
FRA:HPX
65GF Score
Hisamitsu Pharmaceutical Co Inc FRA:HPX
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hisamitsu Pharmaceutical Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Hisamitsu Pharmaceutical Co's Total Liabilities for the fiscal year that ended in Feb. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=275.004+(6.131+72.845
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+41.318+0)
=395.3

Total Liabilities=Total Assets (A: Feb. 2026 )-Total Equity (A: Feb. 2026 )
=2002.681-1607.383
=395.3

Hisamitsu Pharmaceutical Co's Total Liabilities for the quarter that ended in Nov. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=289.082+(7.979+53.542
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+43.579+0)
=394.2

Total Liabilities=Total Assets (Q: Nov. 2025 )-Total Equity (Q: Nov. 2025 )
=1908.568-1514.386
=394.2

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €394.2 Mil mean?
Hisamitsu Pharmaceutical Co (FRA:HPX) has a Total Liabilities of €394.2 Mil as of Nov. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Hisamitsu Pharmaceutical Co and its competitors.
Is Hisamitsu Pharmaceutical Co's Total Liabilities too high?
Hisamitsu Pharmaceutical Co's current Total Liabilities is €394.2 Mil. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 65/100, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's Total Liabilities compare to ESPR and AMPH?
Hisamitsu Pharmaceutical Co's Total Liabilities of €394.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Hisamitsu Pharmaceutical Co and its competitors. Hisamitsu Pharmaceutical Co's current Total Liabilities is €394.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Hisamitsu Pharmaceutical Co (FRA:HPX) has a current Total Liabilities of €394.2 Mil. The stock's GF Value™ is €25.90, compared to a current price of €31.80 — trading 22.8% above its estimated fair value. The current Total Liabilities is €394.2 Mil. Hisamitsu Pharmaceutical Co's overall GF Score™ is 65/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (FRA:HPX), the current Total Liabilities is €394.2 Mil as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hisamitsu Pharmaceutical Co (FRA:HPX) Overvalued in 2026?

Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be overvalued. The current stock price of €31.80 is trading 22.8% above its estimated GF Value™ of €25.90.

Key valuation signals for FRA:HPX:

  • Total Liabilities: €394.2 Mil
  • GF Value™: €25.90 vs. price of €31.80 (22.8% above fair value)
  • GF Score™: 65/100

No single metric tells the full story. See the FRA:HPX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hisamitsu Pharmaceutical Co Business Description

Other Exchanges HTSUY:USA
Address 408 Tashiro Daikancho, Saga Prefecture, Tosu, JPN, 841-0017
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
65GF Score

Get the complete analysis for FRA:HPX

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€31.80
Price
€25.90
GF Value